Zenotech Laboratories Ltd

ZENOTECH

Watchlist

AI Mode

‌

Market Cap

₹ 285 Cr

P/E

99.32

‌

‌
‌

‌

‌
‌

Investment Checklist

How to read checklist?

Performance

STEADY PERFORMER

Valuation

OVERVALUED

Growth

SLUGGISH

Profitability

MODERATE MARGIN

Technicals

Bearish

Risk

MODERATE RISK

Investment Checklist

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

Price

PE Ratio

Price

‌

Overview

Detailed Summary

Zenotech Laboratories Limited specializes in manufacturing pharmaceutical specialty generic injectables. It serves therapeutic areas such as oncology and anesthesiology, providing critical care solutions.

The company has undergone multiple mergers, significantly enhancing its product portfolio, particularly in oncology, with 15 generic chemical oncology products launched in India.

Zenotech's strategic collaboration with Sun Pharmaceutical Industries Limited has resulted in leasing its biotech API facility for R&D activities, reflecting a focus on innovation and growth.

Post its merger with Ranbaxy, Zenotech is under the influence of large promoters, including Daiichi Sankyo, positioning it advantageously in the pharmaceutical sector.

Sector

Pharmaceuticals

Industry

Pharmaceuticals - Indian - Formulations

Market Cap

285 Cr

Volatility

Low Risk

P/E Ratio

99.3

Industry P/E

43.8

PEG Ratio

3.5

P/B Ratio

3.0

52W High

73.50

52W Low

44.75

Sales CAGR

9.14%

5.59%

10.59%

10Y

39.25%

Profit CAGR

28.74%

-36.74%

-12.23%

10Y

—

ROE

TTM

3.19%

9.48%

11.97%

10Y

0.80%

ROCE

TTM

9.08%

13.23%

11.28%

10Y

5.21%

Technicals

‌

Forecasts

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
KERALAYUR	329.00	404 Cr	—	74.02	0.00	-417.29	-15.11	-16.54
BAFNAPH	146.05	352 Cr	33.33	3.86	0.00	11.59	11.00	5.46
ZENOTECH	45.76	285 Cr	99.32	2.96	0.00	3.19	9.08	2.77
SANJIVIN	220.00	264 Cr	35.41	5.89	0.22	16.63	19.07	10.21
SATKARTAR	155.10	246 Cr	25.18	4.77	0.45	23.68	31.80	19.38
BDH	414.75	228 Cr	23.35	3.28	1.14	13.80	18.80	10.96
PHARMAID	49.98	176 Cr	—	3.40	0.00	-31.40	-26.23	-15.87

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

AI Mode

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Sep 2006
Sales	5.27
Expenses	3.98
Operating Profit	1.29
OPM %	24.48
Other Income	0.23
Interest	0.45
Depreciation	0.34
Profit Before Tax	0.73
Tax %	0.00
Net Profit	0.73
EPS in Rs	—

Standalone Profit Loss (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	2.25	11	13	26	22	37	42	41	43	43
Expenses	13	19	17	17	16	19	22	24	29	30
Operating Profit	-10	-7.87	-3.52	8.98	6.38	17	21	17	14	13
OPM %	-461.57	-70.60	-26.99	34.51	28.42	47.75	48.80	42.18	32.94	30.86
Other Income	1.91	2.37	4.71	7.54	0.41	0.63	1.08	1.00	3.47	3.71
Interest	7.50	2.45	0.12	0.89	1.55	1.22	0.11	0.00	0.00	0.00
Depreciation	3.87	3.90	4.20	4.85	6.46	6.97	7.17	7.09	6.96	7.01
Profit Before Tax	-20	-12	-3.13	11	-1.22	9.90	15	11	11	9.93
Tax %	0.00	0.00	0.00	0.00	0.00	-123.97	20.11	25.51	47.50	47.03
Net Profit	-20	-12	-3.13	11	-1.22	22	12	8.30	5.61	5.26
EPS in Rs	-3.26	-1.86	-0.63	1.75	-0.20	3.63	1.90	1.36	0.91	0.50
Dividend Payout %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—

Standalone Balance Sheet (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	34	34	61	61	61	61	61	61	61	61
Reserves	-80	-100	-19	-22	-11	-13	9.61	21	30	35
Borrowings	51	51	0.00	20	19	21	6.00	0.00	0.00	0.00
Other Liabilities	48	65	40	25	17	17	17	19	16	15
Total Liabilities	53	51	82	85	86	86	94	101	106	111
Fixed Assets	48	47	44	43	49	74	71	65	66	61
CWIP	0.00	0.00	2.32	17	29	2.18	0.28	4.98	1.96	3.57
Investments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Assets	4.75	3.91	35	25	7.74	9.43	23	31	39	47
Total Assets	53	51	82	85	86	86	94	101	106	111

Standalone Cash Flows (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	-4.80	1.64	-16	-14	11	5.74	18	21	12	9.49
Cash from Investing Activity	5.50	-0.69	-2.65	-16	-21	-4.82	-1.84	-5.82	-21	15
Cash from Financing Activity	-0.83	-0.72	47	15	-2.70	0.45	-16	-6.11	0.00	0.00
Net Cash Flow	-0.13	0.23	28	-15	-12	1.38	-0.04	8.73	-9.33	25

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Promoters	68.84%	68.84%	68.84%	68.84%	68.84%	68.84%	68.84%	68.84%	68.84%	68.84%	68.84%	68.84%
FIIs	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
DIIs	0.99%	0.99%	0.99%	0.99%	0.99%	0.99%	0.99%	0.99%	0.99%	0.99%	0.99%	0.99%
Public	30.17%	30.17%	30.17%	30.17%	30.17%	30.17%	30.17%	30.17%	30.17%	30.17%	30.17%	30.17%
Total Shareholders	8,746	9,142	9,249	9,589	9,762	9,819	9,750	10,641	10,667	10,690	10,661	10,670

Projection

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Sorry, no results found!

Documents

Presentations

Concalls

Reports

Presentations

No documents found!

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

AI Mode

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

AI Mode

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Sep 2006
Sales	5.27
Expenses	3.98
Operating Profit	1.29
OPM %	24.48
Other Income	0.23
Interest	0.45
Depreciation	0.34
Profit Before Tax	0.73
Tax %	0.00
Net Profit	0.73
EPS in Rs	—

Standalone Profit Loss (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	2.25	11	13	26	22	37	42	41	43	43
Expenses	13	19	17	17	16	19	22	24	29	30
Operating Profit	-10	-7.87	-3.52	8.98	6.38	17	21	17	14	13
OPM %	-461.57	-70.60	-26.99	34.51	28.42	47.75	48.80	42.18	32.94	30.86
Other Income	1.91	2.37	4.71	7.54	0.41	0.63	1.08	1.00	3.47	3.71
Interest	7.50	2.45	0.12	0.89	1.55	1.22	0.11	0.00	0.00	0.00
Depreciation	3.87	3.90	4.20	4.85	6.46	6.97	7.17	7.09	6.96	7.01
Profit Before Tax	-20	-12	-3.13	11	-1.22	9.90	15	11	11	9.93
Tax %	0.00	0.00	0.00	0.00	0.00	-123.97	20.11	25.51	47.50	47.03
Net Profit	-20	-12	-3.13	11	-1.22	22	12	8.30	5.61	5.26
EPS in Rs	-3.26	-1.86	-0.63	1.75	-0.20	3.63	1.90	1.36	0.91	0.50
Dividend Payout %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—

Standalone Balance Sheet (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	34	34	61	61	61	61	61	61	61	61
Reserves	-80	-100	-19	-22	-11	-13	9.61	21	30	35
Borrowings	51	51	0.00	20	19	21	6.00	0.00	0.00	0.00
Other Liabilities	48	65	40	25	17	17	17	19	16	15
Total Liabilities	53	51	82	85	86	86	94	101	106	111
Fixed Assets	48	47	44	43	49	74	71	65	66	61
CWIP	0.00	0.00	2.32	17	29	2.18	0.28	4.98	1.96	3.57
Investments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Assets	4.75	3.91	35	25	7.74	9.43	23	31	39	47
Total Assets	53	51	82	85	86	86	94	101	106	111

Standalone Cash Flows (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	-4.80	1.64	-16	-14	11	5.74	18	21	12	9.49
Cash from Investing Activity	5.50	-0.69	-2.65	-16	-21	-4.82	-1.84	-5.82	-21	15
Cash from Financing Activity	-0.83	-0.72	47	15	-2.70	0.45	-16	-6.11	0.00	0.00
Net Cash Flow	-0.13	0.23	28	-15	-12	1.38	-0.04	8.73	-9.33	25

Oscillators

BearishNeutralBullish

Neutral

Bearish

Pharmaceuticals

Industry

Pharmaceuticals - Indian - Formulations

Market Cap

285 Cr

Volatility

Low Risk

P/E Ratio

99.3

Industry P/E

43.8

PEG Ratio

3.5

P/B Ratio

3.0

52W High

73.50

52W Low

44.75

Sales CAGR

9.14%

5.59%

10.59%

10Y

39.25%

Profit CAGR

28.74%

-36.74%

-12.23%

10Y

—

ROE

TTM

3.19%

9.48%

11.97%

10Y

0.80%

ROCE

TTM

9.08%

13.23%

11.28%

10Y

5.21%